Cargando…
Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138935/ https://www.ncbi.nlm.nih.gov/pubmed/35625763 http://dx.doi.org/10.3390/biomedicines10051026 |
_version_ | 1784714741571125248 |
---|---|
author | Milito, Cinzia Cinetto, Francesco Palladino, Andrea Garzi, Giulia Punziano, Alessandra Lagnese, Gianluca Scarpa, Riccardo Rattazzi, Marcello Pesce, Anna Maria Pulvirenti, Federica Di Napoli, Giulia Spadaro, Giuseppe Carsetti, Rita Quinti, Isabella |
author_facet | Milito, Cinzia Cinetto, Francesco Palladino, Andrea Garzi, Giulia Punziano, Alessandra Lagnese, Gianluca Scarpa, Riccardo Rattazzi, Marcello Pesce, Anna Maria Pulvirenti, Federica Di Napoli, Giulia Spadaro, Giuseppe Carsetti, Rita Quinti, Isabella |
author_sort | Milito, Cinzia |
collection | PubMed |
description | Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease severity in the first two years of the pandemic in a cohort of 471 Primary Antibody Defects adult patients. As secondary endpoints, we compared SARS-CoV-2 annual mortality rate to that observed over a 10-year follow-up in the same cohort, and we assessed the impact of interventions done in the second year, vaccination and anti-SARS-CoV-2 monoclonal antibodies administration on the disease outcome. Forty-one and 84 patients were infected during the first and the second year, respectively. Despite a higher infection and reinfection rate, and a higher COVID-19-related mortality rate compared to the Italian population, the pandemic did not modify the annual mortality rate for any cause in our cohort compared to that registered over the last ten years in the same cohort. PADs patients who died from COVID-19 had an underlying end-stage lung disease. We showed a beneficial effect of MoAbs administration on the likelihood of hospitalization and development of severe disease. In conclusion, COVID-19 did not cause excess mortality in Severe Antibody Deficiencies. |
format | Online Article Text |
id | pubmed-9138935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91389352022-05-28 Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy Milito, Cinzia Cinetto, Francesco Palladino, Andrea Garzi, Giulia Punziano, Alessandra Lagnese, Gianluca Scarpa, Riccardo Rattazzi, Marcello Pesce, Anna Maria Pulvirenti, Federica Di Napoli, Giulia Spadaro, Giuseppe Carsetti, Rita Quinti, Isabella Biomedicines Article Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease severity in the first two years of the pandemic in a cohort of 471 Primary Antibody Defects adult patients. As secondary endpoints, we compared SARS-CoV-2 annual mortality rate to that observed over a 10-year follow-up in the same cohort, and we assessed the impact of interventions done in the second year, vaccination and anti-SARS-CoV-2 monoclonal antibodies administration on the disease outcome. Forty-one and 84 patients were infected during the first and the second year, respectively. Despite a higher infection and reinfection rate, and a higher COVID-19-related mortality rate compared to the Italian population, the pandemic did not modify the annual mortality rate for any cause in our cohort compared to that registered over the last ten years in the same cohort. PADs patients who died from COVID-19 had an underlying end-stage lung disease. We showed a beneficial effect of MoAbs administration on the likelihood of hospitalization and development of severe disease. In conclusion, COVID-19 did not cause excess mortality in Severe Antibody Deficiencies. MDPI 2022-04-29 /pmc/articles/PMC9138935/ /pubmed/35625763 http://dx.doi.org/10.3390/biomedicines10051026 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Milito, Cinzia Cinetto, Francesco Palladino, Andrea Garzi, Giulia Punziano, Alessandra Lagnese, Gianluca Scarpa, Riccardo Rattazzi, Marcello Pesce, Anna Maria Pulvirenti, Federica Di Napoli, Giulia Spadaro, Giuseppe Carsetti, Rita Quinti, Isabella Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy |
title | Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy |
title_full | Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy |
title_fullStr | Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy |
title_full_unstemmed | Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy |
title_short | Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy |
title_sort | mortality in severe antibody deficiencies patients during the first two years of the covid-19 pandemic: vaccination and monoclonal antibodies efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138935/ https://www.ncbi.nlm.nih.gov/pubmed/35625763 http://dx.doi.org/10.3390/biomedicines10051026 |
work_keys_str_mv | AT militocinzia mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT cinettofrancesco mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT palladinoandrea mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT garzigiulia mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT punzianoalessandra mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT lagnesegianluca mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT scarpariccardo mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT rattazzimarcello mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT pesceannamaria mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT pulvirentifederica mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT dinapoligiulia mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT spadarogiuseppe mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT carsettirita mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy AT quintiisabella mortalityinsevereantibodydeficienciespatientsduringthefirsttwoyearsofthecovid19pandemicvaccinationandmonoclonalantibodiesefficacy |